Trial Profile

A Retrospective Study for Evaluation of Real-world Efficacy and Safety of Ramucirumab Plus Paclitaxel in Patients With Locally-advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jun 2022 Results from NCT04192734 and NCT04202328; establishing a data collection framework of EMR-based RWD, evaluate the effectiveness and safety of ramucirumab plus paclitaxel and trastuzumab-emtansine, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
08 Jun 2021 Results evaluating the efficacy, safety, and factors potentially associated with survival in patients with gastric or GEJ adenocarcinoma presented at the 57th Annual Meeting of the American Society of Clinical Oncology
22 Mar 2021 Status changed from not yet recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com